April 27, 2021
Malaria is caused by Plasmodium parasites. Among the 5 disease-causing parasite species, Plasmodium (P.) falciparum and P. vivax are the most widespread. They are transmitted to people through the bites of infected female Anopheles mosquitoes.
According to the World Health Organization (WHO), nearly half of the world’s population was at risk of malaria in 2019. P. falciparum parasites are responsible for most malaria cases in the WHO African region, whereas P. vivax parasites are responsible for most cases in the WHO Region of the Americas.
Over the past 70 years, Sanofi has produced several antimalarial drugs against P. falciparum and P. vivax parasites. In addition, Sanofi has developed a malaria awareness program for school-age children: children may suffer from malaria-induced anemia, a condition which has an impact on their school attendance and cognitive development. These educational tools teach children how to identify and clear the mosquito proliferation sites in their environment. Children can also learn about the clinical symptoms of malaria and the actions to take in case of illness. Education is a key fator in helping to change the health behaviors of these adults of tomorrow, and consequently those of future generations.
Synergy Pharm is proud of providing Sanofi with medical writing support over several years for their various malaria projects, including regulatory and clinical documentation, Common Technical Documents (CTDs) for Marketing Authorization Applications (MAAs), and scientific articles.